Impact of cancer-associated fibroblasts on immunotherapy and liver metastasis in colorectal cancer

Xiaoqing WANG; Jie LONG; Fei WANG; Zhexiong LIAN

doi:10.12449/JCH240618

Volume 40 Issue 6

Jun. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(6): 1183-1190

PDF( 4057 KB)

Impact of cancer-associated fibroblasts on immunotherapy and liver metastasis in colorectal cancer

DOI: 10.12449/JCH240618

1.
School of Medicine，South China University of Technology，Guangzhou 510006，China
2.
Guangdong Cardiovascular Institute，Guangdong Provincial People’s Hospital，Guangzhou 510080，China

Research funding:

Young Scientists Fund of the National Natural Science Foundation of China (82303785);

Young Scientists Fund of the National Natural Science Foundation of China (32100720)

More Information

Corresponding author: LIAN Zhexiong， zxlian@gdph.org.cn （ORCID： 0000-0002-9525-1421）
Received Date: 2023-12-27
Accepted Date: 2024-01-19
Published Date: 2024-06-25

Abstract

Abstract

Objective To investigate the impact of cancer-associated fibroblasts （CAFs） on immunotherapy and liver metastasis in colorectal cancer （CRC）. Methods The single-cell sequencing data （GSE205506） of CRC patients with mismatch repair deficiency （MMRd） were downloaded from the gene expression omnibus database， and R software was used to preprocess the original sequencing data and establish the umap of fibroblast subpopulations， with each subpopulation named based on signature genes. GraphPad was used for the statistical analysis of the proportion of each fibroblast subpopulation， and the key subpopulations with significant differences were analyzed among CRC patients before and after PD-1 immunotherapy， as well as between the patients with pathological complete response （pCR） and those without pCR （non-pCR） after treatment. The analysis of differentially expressed genes and the gene pathway enrichment analysis were performed for the key subpopulations. The TCGA database was used to perform a prognostic and survival analysis of the signature genes of key CAF subpopulations， and RNA sequencing data were used to score and calculate the proportion of key CAF subpopulations in the primary lesions of CRC patients with liver metastasis. The independent-samples t test was used for comparison of normally distributed continuous data between two groups； the Kaplan-Meier method was used to plot survival curves， and the log-rank test was used to calculate survival rates. CellPhoneDB software was used to analyze the receptor-ligand interaction between fibroblast subpopulations and tumor cells， and in vitro cell experiments were used to validate the effect of NRG1， a key ligand molecule， on the migration and invasion abilities of CRC cells. Results After PD-1 immunotherapy for CRC patients， there was a significant reduction in the proportion of F6_MMP1⁺CAFs （P<0.001）， which was only observed in patients achieving complete remission after immunotherapy. F6_MMP1⁺CAFs were upregulated， as well as the genes and signaling pathways associated with tumor migration and invasion， and in addition， there was a significant increase in F6_MMP1⁺CAFs in the tumor tissue of CRC patients with liver metastasis （P<0.000 1）. As a ligand， NRG1 expressed by F6_MMP1⁺CAFs interacted with ERBB3 receptor expressed by tumor cells， and the in vitro experiments confirmed that NRG1 promoted the migration and invasion abilities of tumor cells by activating the ERBB signaling pathway （P<0.05）. Conclusion F6_MMP1⁺CAFs may affect the efficacy of PD-1 immunotherapy in CRC patients and play an important role in promoting liver metastasis in CRC. F6_MMP1⁺CAFs， along with NRG1 that is produced by them and can promote tumor metastasis， can be used as potential therapeutic targets and prognostic markers for CRC.
- Colorectal Neoplasms,
- Neoplasm Metastasis,
- Therapeutics

FullText(HTML)

References(32)

References

[1]	DEKKER E, TANIS PJ, VLEUGELS JLA, et al. Colorectal cancer[J]. Lancet, 2019, 394( 10207): 1467- 1480. DOI: 10.1016/S0140-6736(19)32319-0.
[2]	HUANG XY, SHI GM, ZHOU J. Opportunities and challenges for the treatment of malignant hepatobiliary tumors in the new era of immunotherapy[J]. J Clin Hepatol, 2022, 38( 5): 977- 979. DOI: 10.3969/j.issn.1001-5256.2022.05.001. 黄晓勇, 施国明, 周俭. 免疫治疗新时代下肝胆恶性肿瘤治疗的机遇和挑战[J]. 临床肝胆病杂志, 2022, 38( 5): 977- 979. DOI: 10.3969/j.issn.1001-5256.2022.05.001.
[3]	LE DT, URAM JN, WANG H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372( 26): 2509- 2520. DOI: 10.1056/NEJMoa1500596.
[4]	ZHOU H, LIU ZT, WANG YX, et al. Colorectal liver metastasis: Molecular mechanism and interventional therapy[J]. Signal Transduct Target Ther, 2022, 7( 1): 70. DOI: 10.1038/s41392-022-00922-2.
[5]	MAO XQ, XU J, WANG W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives[J]. Mol Cancer, 2021, 20( 1): 131. DOI: 10.1186/s12943-021-01428-1.
[6]	LI C, TEIXEIRA AF, ZHU HJ, et al. Cancer associated-fibroblast-derived exosomes in cancer progression[J]. Mol Cancer, 2021, 20( 1): 154. DOI: 10.1186/s12943-021-01463-y.
[7]	MANTOVANI A, MARCHESI F, JAILLON S, et al. Tumor-associated myeloid cells: Diversity and therapeutic targeting[J]. Cell Mol Immunol, 2021, 18( 3): 566- 578. DOI: 10.1038/s41423-020-00613-4.
[8]	TANAKA R, KIMURA K, EGUCHI S, et al. Interleukin-8 produced from cancer-associated fibroblasts suppresses proliferation of the OCUCh-LM1 cancer cell line[J]. BMC Cancer, 2022, 22( 1): 748. DOI: 10.1186/s12885-022-09847-z.
[9]	BARRETT T, WILHITE SE, LEDOUX P, et al. NCBI GEO: Archive for functional genomics data sets: Update[J]. Nucleic Acids Res, 2013, 41( Database issue): D991- D995. DOI: 10.1093/nar/gks1193.
[10]	LI JX, WU C, HU HB, et al. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer[J]. Cancer Cell, 2023, 41( 6): 1152- 1169. e 7. DOI: 10.1016/j.ccell.2023.04.011.
[11]	FOLEY CJ, LUO C, O'CALLAGHAN K, et al. Matrix metalloprotease-1a promotes tumorigenesis and metastasis[J]. J Biol Chem, 2012, 287( 29): 24330- 24338. DOI: 10.1074/jbc.M112.356303.
[12]	WAN XY, GUAN SD, HOU YX, et al. FOSL2 promotes VEGF-independent angiogenesis by transcriptionnally activating Wnt5a in breast cancer-associated fibroblasts[J]. Theranostics, 2021, 11( 10): 4975- 4991. DOI: 10.7150/thno.55074.
[13]	MA ZK, LI XD, MAO YZ, et al. Interferon-dependent SLC14A1⁺ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer[J]. Cancer Cell, 2022, 40( 12): 1550- 1565. e 7. DOI: 10.1016/j.ccell.2022.11.005.
[14]	KUMAR V, RAMNARAYANAN K, SUNDAR R, et al. Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer[J]. Cancer Discov, 2022, 12( 3): 670- 691. DOI: 10.1158/2159-8290.CD-21-0683.
[15]	DONATO C, KUNZ L, CASTRO-GINER F, et al. Hypoxia triggers the intravasation of clustered circulating tumor cells[J]. Cell Rep, 2020, 32( 10): 108105. DOI: 10.1016/j.celrep.2020.108105.
[16]	LEQUEUX A, NOMAN MZ, XIAO M, et al. Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy[J]. Oncogene, 2021, 40( 28): 4725- 4735. DOI: 10.1038/s41388-021-01846-x.
[17]	ZHONG BP, CHENG B, HUANG XM, et al. Colorectal cancer-associated fibroblasts promote metastasis by up-regulating LRG1 through stromal IL-6/STAT3 signaling[J]. Cell Death Dis, 2021, 13( 1): 16. DOI: 10.1038/s41419-021-04461-6.
[18]	KALLURI R. The biology and function of fibroblasts in cancer[J]. Nat Rev Cancer, 2016, 16( 9): 582- 598. DOI: 10.1038/nrc.2016.73.
[19]	LI XQ, XU K. Mechanism of cancer-associated fibroblasts promoting tumor metastasis and invasion[J]. Chin J Biochem Mol Biol, 2019, 35( 4): 386- 392. DOI: 10.13865/j.cnki.cjbmb.2019.04.06. 李学勤, 徐克. 肿瘤相关成纤维细胞促进肿瘤侵袭转移的作用机制[J]. 中国生物化学与分子生物学报, 2019, 35( 4): 386- 392. DOI: 10.13865/j.cnki.cjbmb.2019.04.06.
[20]	ZHANG W, WANG HS, SUN MY, et al. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target[J]. Cancer Commun, 2020, 40( 2-3): 69- 80. DOI: 10.1002/cac2.12010.
[21]	ZHOU SL, DAI Z, ZHOU ZJ, et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma[J]. Hepatology, 2012, 56( 6): 2242- 2254. DOI: 10.1002/hep.25907.
[22]	ZHAO JK, OU BC, HAN DP, et al. Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways[J]. Mol Cancer, 2017, 16( 1): 70. DOI: 10.1186/s12943-017-0629-4.
[23]	SUN XT, HE XK, ZHANG Y, et al. Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism[J]. Gut, 2022, 71( 1): 129- 147. DOI: 10.1136/gutjnl-2020-322744.
[24]	XIONG XY, LIAO XY, QIU S, et al. CXCL8 in tumor biology and its implications for clinical translation[J]. Front Mol Biosci, 2022, 9: 723846. DOI: 10.3389/fmolb.2022.723846.
[25]	JONES SA, JENKINS BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer[J]. Nat Rev Immunol, 2018, 18( 12): 773- 789. DOI: 10.1038/s41577-018-0066-7.
[26]	MCANDREWS KM, CHEN Y, DARPOLOR JK, et al. Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer[J]. Cancer Discov, 2022, 12( 6): 1580- 1597. DOI: 10.1158/2159-8290.CD-20-1484.
[27]	HAN Y, ZHANG YY, PAN YQ, et al. IL-1β-associated NNT acetylation orchestrates iron-sulfur cluster maintenance and cancer immunotherapy resistance[J]. Mol Cell, 2023, 83( 11): 1887- 1902. e 8. DOI: 10.1016/j.molcel.2023.05.011.
[28]	ZHANG ZD, KARTHAUS WR, LEE YS, et al. Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer[J]. Cancer Cell, 2020, 38( 2): 279- 296. e 9. DOI: 10.1016/j.ccell.2020.06.005.
[29]	WEI DY, GENG F, LIANG SM, et al. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells[J]. Biosci Rep, 2017, 37( 2): BSR20160470. DOI: 10.1042/BSR20160470.
[30]	XU QX, CHIAO P, SUN Y. Amphiregulin in cancer: New insights for translational medicine[J]. Trends Cancer, 2016, 2( 3): 111- 113. DOI: 10.1016/j.trecan.2016.02.002.
[31]	EREZ N, TRUITT M, OLSON P, et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner[J]. Cancer Cell, 2010, 17( 2): 135- 147. DOI: 10.1016/j.ccr.2009.12.041.
[32]	QI JJ, SUN HX, ZHANG Y, et al. Single-cell and spatial analysis reveal interaction of FAP⁺ fibroblasts and SPP1⁺ macrophages in colorectal cancer[J]. Nat Commun, 2022, 13( 1): 1742. DOI: 10.1038/s41467-022-29366-6.

Relative Articles

[1]	Ji WeiJia, Yan XueBing. Clinical effect and safety of pegylated interferon-α-2a versus pegylated interferon-α-2b in treatment of chronic hepatitis B [J]. Journal of Clinical Hepatology, 2019, 35(2): 309-314. doi: 10.3969/j.issn.1001-5256.2019.02.013
[2]	Chen XiaoYun, Zheng YanHong, Jin Yi, Yu HaiBin, Ma LiNa, Chen XinYue. Correlation between routine blood test results and antiviral effect in patients with refractory chronic hepatitis C treated with pegylated interferon-α[J]. Journal of Clinical Hepatology, 2016, 32(7): 1319-1322. doi: 10.3969/j.issn.1001-5256.2016.07.021
[4]	Wang TingTing, Jiang YingAn, Yang LiHua, Zhou ZhenDong. Efficacy and safety of pegylated interferon in patients with chronic hepatitis C in China: meta- analysis[J]. Journal of Clinical Hepatology, 2013, 29(11): 824-827. doi: 10.3969/j.issn.1001-5256.2013.10.006
[5]	Jiang XueQiang, Zou XiaoJing, Tian DeYing. Virological response of chronic hepatitis C treated with peg-interferon α-2a and Ribavirin[J]. Journal of Clinical Hepatology, 2011, 27(4): 417-419.
[6]	Zheng YingYing, Fan XiaoHong, Wang LiFen, Tian Di, Huo Na, Lu HaiYing, Wu ChiHong, Xu XiaoYuan, Wei Lai. Efficacy and side effects of PEG-IFNα-2a plus ribavirin on elderly patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(8): 821-823.
[7]	Zhao Ping, Wang JiangBin, Jiao Jian. Response to PEG-IFN α-2a by chronic hepatitis C patients with autoimmune features[J]. Journal of Clinical Hepatology, 2010, 26(4): 374-376.
[8]	Zhou XianShan, Hong HuiLan. Clinical analysis of elderly patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2008, 24(5): 364-366.
[9]	Guo HaiYan, Chen Ming, Wang LiPing, Ge GuoHong, Zhang YanChao. Recent thymic output function in patients with chronic hepatitis C by real time fluorescence quantitative PCR analysis[J]. Journal of Clinical Hepatology, 2007, 23(6): 432-433.
[10]	Cheng QianGang, Zhao HaiHong. Clinlical effect and safety of PegIFN α-2a in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2007, 23(6): 424-426.
[12]	Pei Bin, Chen ZhangRong, Huang WenQi, Xie JinZhen. The change of Th1/Th2 cytokines expression in treatment of chronic hepatitis C with IFN-α and ribavirin[J]. Journal of Clinical Hepatology, 2006, 22(3): 188-190.
[13]	Jiao Jian, Wang JiangBin. Association between HLA-DRB and chronic hepatitis C infection and its effect on the response to interferon alpha and ribavilin therapy[J]. Journal of Clinical Hepatology, 2004, 20(6): 329-331.
[16]	Shao ChunZhong, Chen XiaoXia, Yuan XiXia, Su Jing, Zheng JunMei, Li Ying. Observation on the effect of α-2b interferon and ribavirin and thymus peptide joint treatment for the 30 patients with chronic hepatitis C.[J]. Journal of Clinical Hepatology, 2002, 18(3): 183-184.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4)

Get Citation

PDF

XML

Article Metrics

Article views (690) PDF downloads(57)

Impact of cancer-associated fibroblasts on immunotherapy and liver metastasis in colorectal cancer

DOI: 10.12449/JCH240618

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Impact of cancer-associated fibroblasts on immunotherapy and liver metastasis in colorectal cancer

DOI: 10.12449/JCH240618

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content